Showing 4091-4100 of 7280 results for "".
- Practical Dermatology® Magazine Launches Daily Coverage of Denver Annual Meetinghttps://practicaldermatology.com/news/20140324-practical_dermatology_magazine_launches_daily_coverage_of_denver_annual_meeting/2459297/Bryn Mawr Communications III, LLC's Practical Dermatology® magazine and DermTube.com this weekend launched daily video coverage of the Annual Meeting in Denver with host Joel L. Cohen, MD, FAAD. Dr. Cohen,
- Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140324-anti-interleukin-23_monoclonal_antibody_guselkumab_significant_efficacy_in_moderate_to_severe_plaque_psoriasis/2459298/New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal a
- ADAM Names June McKernan “Practice Manager Of The Year”https://practicaldermatology.com/news/20140323-adam_names_june_mckernan_practice_manager_of_the_year/2459299/The Association of Dermatology Administrators and Managers (ADAM) named June McKernan, Administrator, of Patient Preferred Dermatology of Los Alamitos, CA, the recipient of the organization's inaugural Practice Manager of the Year award. She w
- Launch of TrueLipids® Made with Zemea® Propanediolhttps://practicaldermatology.com/news/20140320-launch_of_truelipids_made_with_zemea_propanediol/2459307/Cheryl Lee, MD, Sensitive Skin Care, is soon launching its patent-pending line, TrueLipids® therapeutic products. TrueLipids, now made with Zemea® is designed to repair disrupted skin barriers and promote lipid production, while being cosmetically friendly to the skin. This new li
- Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangiomahttps://practicaldermatology.com/news/20140319-pierre_fabre_obtains_fda_approval_to_market_hemangeol_for_the_treatment_of_infantile_hemangioma/2459311/Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for “proliferating infantile hemangioma requiring s
- Doctors Issue New Treatment Guidelines for Skin Abscesses Caused By MRSAhttps://practicaldermatology.com/news/20140317-doctors_issue_new_treatment_guidelines_for_skin_abscesses_caused_by_mrsa/2459315/It has been more than 10 years since the clinical battle began with community-acquired methicillin-resistant Staphylococcus aureus (MRSA), and doctors are still grappling with how to diagnose, treat and prevent this virulent form of staph infection, which is immune to man
- Phase I Trial of Nivolumab Shows Long-Term Efficacy Against Melanomahttps://practicaldermatology.com/news/20140313-phase_i_trial_of_nivolumab_shows_long-term_efficacy_against_melanoma/2459318/A recent study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions, published online in the Journal of Clinical Oncology, provides the longest-term look so far at how melanom
- Deepak Chadha is New Vice President of Regulatory Affairs for Suneva Medicalhttps://practicaldermatology.com/news/20140311-deepak_chadha_is_new_vicepresident_of_regulatory_affairs_for_suneva_medical/2459319/Suneva Medical appointed Deepak Chadha to Vice President of Regulatory Affairs. Chadha's role will be leading the development and implantation of regulatory practices. Chairman and Chief Executive Officer, Nicholas L. Teti, Jr. said, “Deepak has been responsible for several global regula
- Antares Pharma Announces LEO Pharma's Launch of Otrexup (Methotrexate) Injection for Adults with Psoriasishttps://practicaldermatology.com/news/20140311-antares_pharma_announces_leo_pharmas_launch_of_otrexup_methotrexate_injection_for_adults_with_psoriasis/2459320/Antares Pharma, Inc. announced LEO Pharma's launch of Otrexup, the first FDA-approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. "We are very pleased that
- Aquavit Pharmaceuticals Appoints David J. Goldberg as Chief Medical Officerhttps://practicaldermatology.com/news/20140305-aquavit_pharmaceuticals_appoints_david_j_goldberg_as_chief_medical_officer/2459324/Aquavit Pharmaceuticals, Inc., appointed David J. Goldberg, MD, JD as its Chief Medical Officer. Dr. Goldberg is recognized nationally and internationally for his innovative work with skin lasers, cosmetic dermatology and facial rejuvenation techniques. Prior to joining Aquavit,